Mec. Agnieszka Zejda-Harańczyk
Kierownik Działu PrawnegoW pełni certyfikowana jako adwokat w 2012 r. Specjalizuje się w prawie medycznym, korporacyjnym i międzynarodowym. Studia prawnicze odbyła w Katowicach i Zurychu.
Kadra zarządzająca
-
Prof. dr hab. n. med. Paweł Buszman, EMBA
założyciel, Prezes Zarządu, Kierownik i Główny BadaczWięcej -
Dr n. o zdr. Piotr Hirnle, MSc
udziałowiec, Członek Zarządu, Dyrektor Finansowy, Dyrektor B+RWięcej -
Prof. dr hab. n. med. Piotr Buszman
współzałożyciel, Członek Zarządu, Dyrektor MedycznyWięcej -
Mec. Agnieszka Zejda-Harańczyk
Kierownik Działu PrawnegoWięcej
partner with us
Improving the lives of patients by developing proprietary, innovative
In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
Clinical trials completed and medical device certification obtained, enterprise value at EUR 180m. Exit strategy: second public offering on a selected stock exchange abroad e.g. Euronext, London Stock Exchange, alternatively a merger & acquisition deal
Our Partners
-
MerckIn the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
-
Pfizer Eastern EuropeIn the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
-
AlconIn the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
-
Community FoundationIn the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
become our partner